The vascular endothelial growth factor is the target of the antiangiogenic drug bevacizumab. Another protein, placental growth factor, also represents a promising target for countering tumor angiogenesis.
No takes yet. Share an insight, caveat, or question.
Gregg L. Semenza (2008) studied this question.